Evaluation of the effects of Moringa oleifera extract on viability and caspase 3 activity in EL4 lymphoma cell line

Document Type : Full Research Paper

Authors

1 Department of Pathobiology, Science and Research Branch, Islamic Azad University, Tehran, Iran.

2 aDepartment of Pathobiology, Science and Research Branch, Islamic Azad University, Tehran, Iran.

Abstract

Introduction: Lymphoma is one of the types of malignant cancers in veterinary medicine and has a high prevalence rate in dogs and cats that are involved in weak immune systems. Due to the side effects of chemotherapy drugs, the use of plants with medicinal properties has received much attention from researchers. The Moringa oleifera plant has been found to have anti-inflammatory properties.
Objectives: The purpose of this study was to investigate the toxicity effect of moringa plant extract on the EL4 cell line from murine lymphoma in order to investigate the anticancer effects within the scope of this research.
Materials and methods: In this study, after preparing Moringa oleifera plant powder extract, EL4 cells were exposed to different concentrations of Moringa plant at 24, 48, and 72 hours. The survival rate of cell groups was firstly analyzed by the trypan blue staining method and then by MTT broch cytotoxicity, and the next step was the expression of the caspase-3 gene by the real-time PCR method. Data analysis was done using GraphPad Prism9 software and a one-way ANOVA test.
Results: Cell line treatment with Moringa plant powder extract in all studied concentrations led to inhibition of cancer cell growth. The highest level of effectiveness was observed at different times and at a concentration of 40 μg/ml, and its IC 50 was above 50%.
Conclusion: Moringa oleifera plant extract, especially at a concentration of 40 μg/ml and a duration of up to 72 hours, can inhibit the growth of EL4 lymphoma cancer cells.

Keywords

Main Subjects

Veterinary Research & Biological Products
Volume 38, Issue 3
October 2025
Pages 24-36

Files

History

  • Receive Date: 29 November 2024
  • Revise Date: 02 February 2025
  • Accept Date: 04 February 2025

Share

How to cite

Statistics